Increased Intestinal Permeability Is Associated With Later Development of Crohn’s Disease

Williams Turpin, Sun-Ho Lee, Juan A. Raygoza Garay, +89

Gastroenterology

InflammationChronic Inflammatory DiseasesIntestinal Permeability IsMucosal ImmunologyCrohn ’ +9

American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21–23, 2006

Jean‐Frédéric Colombel, Brian Feagan, Richard N. Fedorak, +11

Gastroenterology

InflammationTranslational MedicineMucosal ImmunologyImmunologyGastroenterology +4

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Laurent Peyrin‐Biroulet, Ailsa Hart, Peter Bossuyt, +323

˜The œLancet. Gastroenterology & hepatology

InflammationAnti-inflammatoryImmunologyGastroenterologyMaintenance Therapy +5

A Randomized Trial of Methotrexate in Combination With Infliximab for the Treatment of Crohn's Disease

Brian Feagan, John WD McDonald, Remo Panaccione, +18

Gastroenterology

Anti-inflammatoryImmunologyGastroenterologyRandomized TrialUlcerative Colitis +2

Management of Recent Onset Crohn’s Disease: A Controlled, Randomized Trial Comparing Step-up and Top-down Therapy

Daniël W. Hommes, Filip Baert, Gert Van Assche, +9

Gastroenterology

GastroenterologyClinical GastroenterologyTop-down TherapyMedicineTreatment Development +1

Use of anti-tumour necrosis factor agents in inflammatory bowel disease

Stefan Schreiber, Massimo Campieri, Jean‐Frédéric Colombel, +17

International Journal of Colorectal Disease

InflammationAnti-inflammatoryAutoimmune DiseaseMedicineImmunology +7

Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn’s Disease

Niels Vande Casteele, Diane R. Mould, Jason Coarse, +4

Clinical Pharmacokinetics

Pharmacokinetic VariabilityCrohn ’Gastrointestinal PharmacologyMedicineGastroenterology +3

Maintenance infliximab (Remicade) is safe, effective and steroid-sparing in Crohn's disease: Preliminary results from the accent i trial

Stephen B. Hanauer, Gary R. Lichtenstein, J-F. Columbel, +8

Gastroenterology

InflammationChronic Inflammatory DiseasesAnti-inflammatoryMaintenance InfliximabImmunology +6

A randomized, placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-α, in patients with moderate to severe Crohn's disease

William J. Sandborn, Brian Feagan, Graham Radford-Smith, +3

Gastroenterology

InflammationImmunologyGastroenterologyPathologyPlacebo-controlled Trial +7

P-105 The Effect of Vedolizumab on Extraintestinal Manifestations in Patients with Crohnʼs Disease in GEMINI 2

David T. Rubin, Brian Feagan, Gerald W. Dryden, +6

Inflammatory Bowel Diseases

Gastrointestinal PharmacologyDb VdzImmunologyGastroenterologyPathology +16